UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update

Journal of clinical oncology, 2021-12, Vol.39 (35), p.3959-3977

2021

Volltextzugriff (PDF)

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

Journal of clinical oncology, 2016-09, Vol.34 (25), p.3069-3103

2016

Volltextzugriff (PDF)

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

Journal of clinical oncology, 2012-07, Vol.30 (21), p.2585-2592

2012

Volltextzugriff (PDF)

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1124-1130

2010

Volltextzugriff (PDF)

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

Journal of clinical oncology, 2010-03, Vol.28 (8), p.1301-1307

2010

Volltextzugriff (PDF)

American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

Journal of clinical oncology, 2010-08, Vol.28 (23), p.3784-3796

2010

Volltextzugriff (PDF)

Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab

Journal of clinical oncology, 2011-02, Vol.29 (6), p.632-638

2011

Volltextzugriff (PDF)

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Journal of clinical oncology, 2008-04, Vol.26 (11), p.1810-1816

2008

Volltextzugriff (PDF)

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays

Journal of clinical oncology, 2011-08, Vol.29 (24), p.3328-3330

2011

Volltextzugriff (PDF)

American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer

Journal of clinical oncology, 2005-10, Vol.23 (30), p.7703-7720

2005

Volltextzugriff (PDF)

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Journal of clinical oncology, 2008-04, Vol.26 (12), p.1993-1999

2008

Volltextzugriff (PDF)

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

Journal of clinical oncology, 2005-01, Vol.23 (3), p.619-629

2005

Volltextzugriff (PDF)

Anthracyclines in Early Breast Cancer: The Long Goodbye

Journal of clinical oncology, 2024-11

2024

Volltextzugriff (PDF)

Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update

Journal of clinical oncology, 2023-06, Vol.41 (18), p.3423-3425

2023

Volltextzugriff (PDF)

Quality of Non–Breast Cancer Health Maintenance Among Elderly Breast Cancer Survivors

Journal of clinical oncology, 2003-04, Vol.21 (8), p.1447-1451

2003

Volltextzugriff (PDF)

Adjuvant Endocrine Therapy for Women With Hormone Receptor―Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

Journal of clinical oncology, 2014-07, Vol.32 (21), p.2255-2269

2014

Volltextzugriff (PDF)

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

Journal of clinical oncology, 2003-08, Vol.21 (15), p.2889-2895

2003

Volltextzugriff (PDF)

Contrary Effects of the Receptor Tyrosine Kinase Inhibitor Vandetanib on Constitutive and Flow-Stimulated Nitric Oxide Elaboration in Humans

Hypertension (Dallas, Tex. 1979), 2011-07, Vol.58 (1), p.85-92

2011

Volltextzugriff (PDF)

American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays

Journal of clinical oncology, 2004-09, Vol.22 (17), p.3631-3638

2004

Volltextzugriff (PDF)

Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?

Journal of clinical oncology, 2012-06, Vol.30 (18), p.2179-2182

2012

Volltextzugriff (PDF)

Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Journal of clinical oncology, 2014-05, Vol.32 (13), p.1365-1383

2014

Volltextzugriff (PDF)

Past, present, and future challenges in breast cancer treatment

Journal of clinical oncology, 2014-07, Vol.32 (19), p.1979-1986

2014

Volltextzugriff (PDF)

Bevacizumab for advanced breast cancer: all tied up with a RIBBON?

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1232-1235

Burstein, Harold J

2011

Volltextzugriff (PDF)

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Journal of clinical oncology, 2019-08, Vol.37 (22), p.1868-1875

2019

Volltextzugriff (PDF)

Cancer-Related Direct-to-Consumer Advertising: Awareness, Perceptions, and Reported Impact Among Patients Undergoing Active Cancer Treatment

Journal of clinical oncology, 2009-09, Vol.27 (25), p.4182-4187

2009

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Aktive Filter

ThemaChemotherapy

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(58)

Sprache

Englisch
(58)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(49)
Science & Technology
(49)
Oncology
(48)
Humans
(45)
Female
(43)
Breast Neoplasms - Drug Therapy
(37)
Biological And Medical Sciences
(29)
Medical Sciences
(29)
Tumors
(25)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(23)
Middle Aged
(21)
Gynecology. Andrology. Obstetrics
(19)
Mammary Gland Diseases
(19)
Aged
(16)
Breast Neoplasms - Pathology
(16)
Chemotherapy, Adjuvant
(16)
Adult
(15)
Disease-Free Survival
(12)
Antineoplastic Agents - Therapeutic Use
(10)
Antineoplastic Agents, Hormonal - Therapeutic Use
(10)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Journals@Ovid Full Text
(57)
EZB Electronic Journals Library
(56)
Ingenta.com
(56)
Publisher or Other Site
(54)
MEDLINE
(46)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(1)
Elsevier ScienceDirect Journals Complete
(1)
Springer Online Journals
(1)

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays

American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

Anthracyclines in Early Breast Cancer: The Long Goodbye

Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update

Quality of Non–Breast Cancer Health Maintenance Among Elderly Breast Cancer Survivors

Adjuvant Endocrine Therapy for Women With Hormone Receptor―Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

Contrary Effects of the Receptor Tyrosine Kinase Inhibitor Vandetanib on Constitutive and Flow-Stimulated Nitric Oxide Elaboration in Humans

American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays

Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?

Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Past, present, and future challenges in breast cancer treatment

Bevacizumab for advanced breast cancer: all tied up with a RIBBON?

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Cancer-Related Direct-to-Consumer Advertising: Awareness, Perceptions, and Reported Impact Among Patients Undergoing Active Cancer Treatment

Aktive Filter

Suchergebnisse filtern